# Mark Lakshmanan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-lakshmanan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,806 |
| Field | Diabetes Treatment and Management |
| h-index | 30 |
| i10-index | 47 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5055443598 |
| ORCID iD | 0000-0002-6578-9570 |
| Works | 79 |

## Researcher papers

- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial](https://scholariq.org/papers/dulaglutide-versus-insulin-glargine-in-patients-with-type-2-diabetes-and/)
- [Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-analysis-of-the/)
- [Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures](https://scholariq.org/papers/teriparatide-for-acceleration-of-fracture-repair-in-humans-a-prospective/)
- [Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)](https://scholariq.org/papers/efficacy-and-safety-of-dulaglutide-added-onto-pioglitazone-and-metformin-versus/)
- [Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial](https://scholariq.org/papers/effect-of-dulaglutide-on-cognitive-impairment-in-type-2-diabetes-an-exploratory/)
- [Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide](https://scholariq.org/papers/design-and-baseline-characteristics-of-participants-in-the-scp-r-scp-esearching/)
- [The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial](https://scholariq.org/papers/the-effect-of-dulaglutide-on-stroke-an-exploratory-analysis-of-the-rewind-trial/)
- [HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression](https://scholariq.org/papers/hba1c-change-and-diabetic-retinopathy-during-glp-1-receptor-agonist/)
- [The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures](https://scholariq.org/papers/the-effect-of-teriparatide-compared-with-risedronate-on-reduction-of-back-pain/)
- [Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)](https://scholariq.org/papers/body-weight-and-egfr-during-dulaglutide-treatment-in-type-2-diabetes-and/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Thyroid Cancer Diagnosis and Treatment](https://scholariq.org/topics/thyroid-cancer-diagnosis-and-treatment/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.